Land: Suður-Afríka
Tungumál: enska
Heimild: South African Health Products Regulatory Authority (SAHPRA)
Roussel
TARGOCID FOR INJECTION TARGOCID SOLVENT SCHEDULING STATUS: S4/S1 PROPRIETARY NAME (and dosage form): TARGOCID FOR INJECTION TARGOCID SOLVENT COMPOSITION: TARGOCID FOR INJECTION: Per vial: Lyophilised Teicoplanin 200 mg TARGOCID SOLVENT: Per ampoule: Water for Injection 3 mL Reconstitute before use. The resultant solution is isotonic. PHARMACOLOGICAL CLASSIFICATION: A 20.1.1. Broad and medium spectrum antibiotics PHARMACOLOGICAL ACTION: TARGOCID (lyophilised teicoplanin) is a bactericidal, glycopeptide antibiotic, produced by fermentation of Actinoplanes teicomyceticus. It is active in vitro against both aerobic and anaerobic Gram-positive bacteria. Species usually sensitive: Staphylococcus aureus, coagulase negative staphylococci (sensitive or resistant to methicillin), streptococci, enterococci, Listeria monocytogenes, micrococci, group JK Corynebacteria, Gram-positive anaerobes including Clostridium difficile and peptococci. Species usually resistant: Nocardia asteroides, lactobacillus spp., Leuconostoc and all Gram-negative bacteria. Bactericidal synergy has been demonstrated in vitro, in combination with aminoglycosides, against group D streptococci and staphylococci. In vitro combinations of TARGOCID with rifampicin or fluorinated quinolones show primarily additive effects and sometimes synergy. One-step resistance to TARGOCID could not be obtained in vitro, and multi-step resistance was only reached in vitro after 11 to 14 passages. TARGOCID does not show cross-resistance with other classes of antibiotics. Following intravenous and intramuscular administration, TARGOCID is widely distributed in body tissues. It is slowly eliminated with a plasma half-life of 70 to 100 hours; the excretory route is renal. TARGOCID is not absorbed when administered orally. TARGOCID does not penetrate through the blood-brain b Lestu allt skjalið